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Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease of 
the central nervous system. Over the past two decades, MS has gone from an essentially 
untreatable condition, to one for which there are an increasing number of highly effective 
treatments that suppress relapses (episodes of new neurological symptoms that evolve over 
hours to days). There has been less success treating the progressive component of MS - 
characterised by an unremitting, albeit usually slow, accrual of neurological deficit - and 
while recent trials have shown some early promise (for example simvastatin at phase 2 
[Chataway et al. 2014] and ocrelizumab at phase 3 [Montalban et al. 2015]), there are 
currently no licensed treatments to treat progressive MS.  
 
Inflammatory demyelinating lesions in the white matter of the central nervous system (CNS) 
are the most readily identified pathological hallmark of MS, and their development leads to 
symptomatic relapses. However, it is increasingly recognised that grey matter lesions 
maybe as, and perhaps more, extensive than those in white matter (but they are much more 
difficult to see using magnetic resonance imaging [MRI]), and MS-associated brain atrophy 
can be substantial: It is now clear that clinical outcomes in MS represent a complicated 
interplay of immune mediated inflammation and neurodegeneration. Currently available MS 
disease modifying treatments (DMTs) have been assessed based on their ability to suppress 
white matter lesion formation and licensed based on their effect on relapses. 
 
Most treatments that are now used in MS were first developed for use in other conditions, 
and given the significant role the immune system plays in MS, it is unsurprising that most 
have been developed to suppress inflammation. There are now three licensed oral agents 
for the treatment of relapsing-remitting MS: dimethyl fumarate [Tecfidera], fingolimod 
[Gilenya] and teriflunomide [Aubagio] (Table 1). These are all at least as, and probably more, 
effective as the first line injectable agents (beta-interferon and glatiramer acetate) and are 
more convenient to administer, but they require greater blood test monitoring, 
pharmacovigilance and neurological oversight.  
 
Fingolimod [Gilenya] was the first oral agent to be approved by National Institute for Health 
and Care Excellence (NICE; www.nice.org.uk/Guidance/ta254) for use in people who had 
not responded adequately to treatment with beta-interferon and is a good example of the 
change in our practice that has arisen as a result of the introduction of such drugs. Beta-
interferon is usually started as an outpatient, is commonly associated with 'flu'-like symptoms 
after injections and occasionally local injection site reactions, and we monitor with six-
monthly full blood counts (to look for lymphopenia) and liver function tests. In contrast, 
because of potentially fatal (though rare) first dose heart block, fingolimod is started with 6 
hourly electrocardiogram monitoring, and if treatment is missed for more than a day in the 
first two weeks, or three days after this, then treatment is restarted with the same cardiac 
monitoring protocol. We undertake blood tests every three months to assess lymphocyte 
counts (which are reversibly reduced due to mechanism of action of fingolimod) and liver 
function. Other side effects of fingolimod that require active assessment include macular 
oedema (particularly in diabetics), which we screen for even in asymptomatic people after 
three months on treatment, and regular skin inspection for basal cell carcinoma (now 
recommended yearly, www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/002202/WC500104528.pdf). 
 
Dimethyl fumarate [Tecfidera] (www.nice.org.uk/guidance/ta320) does not require 
particular first dose precautions, but also requires more frequent blood test monitoring than 
beta-interferon (for liver dysfunction and suppression of lymphocytes). Similarly 
  
Teriflunomide [Aubagio] (www.nice.org.uk/guidance/ta303) is also straightforward to start, 
but initially requires frequent blood monitoring (every 2 weeks for the first 6 months) due to 
potential adverse effects on liver function, and it can also suppress white blood cell counts. 
While we recommend that all women taking any DMTs avoid conception, there are specific 
concerns about pregnancy in women taking teriflunomide which has a clear teratogenic 
warning (www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/002514/WC500148682.pdf). Moreover it may persist in the 
body for years, and it may take up to two years to drop to a level where it is thought safe to 
attempt conception, although it can be actively removed with cholestyramine.  
 
While the interferons and glatiramer acetate have proven to be essentially free of long-term 
serious side effects, experience with natalizumab [Tysabri] (given by monthly IV infusion) 
highlights the need for care when adopting new agents wholesale. Since the pivotal trials 
(Polman et al. 2006), we now know that there is clear risk of developing progressive 
multifocal leucoencephalopathy (PML), which is fatal in about 20% and associated with 
severe persistent neurological disability in about 30% of people who develop it (Baldwin et 
al. 2013). PML is due to reactivation of the John Cunningham virus (JCV) infection in the 
central nervous system (CNS) and depend both on the duration of treatment and if 
immunosuppressive treatments (such as mitoxantrone) have previously been used. In those 
who are JCV sero-positive (about half the population), and who have not previously taken 
an immunosuppressant, the estimated risk of developing PML within 2 years of starting 
treatment with natalizumab is ~0.06%, rising to ~ 0.52% beyond 2 years  (McGuigan et al. 
2016). Prior immunosuppressant use appears to at least double the risk  of developing PML 
(McGuigan et al. 2016). There are now a handful of reports of PML in people taking 
fingolimod 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/n
ews_detail_002447.jsp&mid=WC0b01ac058004d5c1) or dimethyl fumarate 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/10/n
ews_detail_002423.jsp&mid=WC0b01ac058004d5c1), albeit seemingly much less often 
than in those taking natalizumab, but with the caveat that oral DMTs have been in 
widespread use for less time.  
 
In conclusion, while the introduction of oral DMTs for MS brings provides very welcome 
additional options, along with more convenient administration, they require greater 
monitoring and a clear commitment from people taking them to fully engage with and share 
responsibility for this. It means that all clinicians treating people with MS need to be much 
more aware of the medications they are taking, as starting and stopping these new oral 
DMTs is not necessarily as straightforward as injectable agents, and they may have 
significant drug interactions and side effects that require urgent review. Alongside the 
addition of highly active infusion treatments for MS which are not discussed here 
(alemtuzumab and natalizumab), this has major implications for the configuration of MS 
services which need to be safe and effective. It is truly a new dawn for MS therapeutics.  
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Table 1: Current oral DMTs approved by NICE for use in MS. 
 
 
Agent Year of 
approval 
by EMA 
Dosing Reduction in 
annualized 
relapse rate 
compared with 
placebo (to 
nearest 5%, NICE 
appraisal) 
1st line use? Side effects 
fingolimod 
(Gilenya) 
2011 0.5 mg od 50% No, for 2nd line 
use if 
treatment 
failure 
Deranged LFTs, 
lymphopenia, 
rare macular 
oedema,heart 
block and BCC, 
very rare PML 
teriflunomide 
(Aubagio) 
2013 14 mg od 30% Yes but not 
for highly 
active disease 
Diarrhoea, 
alopecia, 
nausea, 
deranged LFTs, 
potentially 
teratogenic 
dimethyl fumarate 
(Tecfidera) 
2014 240 mg bd 45% Yes but not 
for highly 
active disease 
Flushing, 
gastrointestinal 
symptoms, 
lymphopenia, 
deranged LFTs, 
very rare PML  
 
 
BCC = Basal cell carcinoma 
EMA = European Medicines Agency 
LFTs = liver function tests 
NICE = National Institute for Health and Care Excellence 
PML = progressive multifocal leucoencephalopathy  
